ENGN
enGene Therapeutics Inc.
enGene Therapeutics Inc. insider trading
Insiders at enGene Therapeutics Inc. have been buying its stock on the open market. The largest purchase in the last 30 days was Grossman William (Interim Chief Medical Officer · Director) buying $10.1K of ENGN, filed Sep 24, 2026. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
- Bought on the open market
- $10.1K
- Sold
- —
- Insiders
- 1
- Latest trade
- Sep 22, 2026
From SEC filings · last 30 days
Recent ENGN insider transactions
Grossman WilliamInterim Chief Medical Officer · Director
Bought 5,102 sh at $1.97 · Sep 22, 2026
$10.1K
Filing
SEC Form 4 data, Q3 2024 to Q2 2026
ENGN insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 3 insiders traded ENGN on the open market: 11 purchases worth $7.9M and 0 sales. In the last four quarters alone: no open-market trades at all.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | — | |
| Q3 2025 | — | — | |
| Q2 2025 | — | — | |
| Q1 2025 | — | — | |
| Q4 2024 | +$5.5M7 buys | — | |
| Q3 2024 | +$2.5M4 buys | — |
- Largest purchase
- +$5M of ENGN by Forbion Growth Management B.V. (10% Owner) on Oct 30, 2024.
Open-market transactions through Jun 30, 2026most recent first
Forbion Growth Management B.V.
10% Owner
+$5M
Oct 30, 2024
561,797 sh · $8.90
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$5.3K
Oct 08, 2024
800 sh · $6.60
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$77.6K
Oct 07, 2024
11,844 sh · $6.55
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$39.2K
Oct 04, 2024
5,997 sh · $6.54
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$37.4K
Oct 03, 2024
5,769 sh · $6.48
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$64.7K
Oct 02, 2024
10,153 sh · $6.37
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$227.2K
Oct 01, 2024
35,279 sh · $6.44
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$2.2M
Sep 30, 2024
341,332 sh · $6.34
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$228.1K
Sep 27, 2024
38,396 sh · $5.94
Cooper Ronald Harold Wilfred
Chief Executive Officer · Director
+$57K
Sep 27, 2024
10,000 sh · $5.70
Forbion Growth Opportunities Fund I Cooperatief U.A.
10% Owner
+$20.7K
Sep 27, 2024
3,243 sh · $6.38
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Oct 30, 2024 | Forbion Growth Management B.V.10% Owner | 561,797 | $8.90 | +$5M |
| Oct 08, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 800 | $6.60 | +$5.3K |
| Oct 07, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 11,844 | $6.55 | +$77.6K |
| Oct 04, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 5,997 | $6.54 | +$39.2K |
| Oct 03, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 5,769 | $6.48 | +$37.4K |
| Oct 02, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 10,153 | $6.37 | +$64.7K |
| Oct 01, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 35,279 | $6.44 | +$227.2K |
| Sep 30, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 341,332 | $6.34 | +$2.2M |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 38,396 | $5.94 | +$228.1K |
| Sep 27, 2024 | Cooper Ronald Harold WilfredChief Executive Officer · Director | 10,000 | $5.70 | +$57K |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner | 3,243 | $6.38 | +$20.7K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check ENGN — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
enGene Therapeutics Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- Are ENGN insiders buying or selling?
- Between Sep 22, 2026 and Sep 22, 2026, 1 enGene Therapeutics Inc. insider made 1 open-market purchase worth $10.1K and no sales, a net purchase of $10.1K.
- How much ENGN stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 3 enGene Therapeutics Inc. insiders made 11 open-market purchases worth $7.9M and no sales. In the four quarters to Jun 30, 2026: no purchases and no sales. The largest purchase was Forbion Growth Management B.V. buying $5M on Oct 30, 2024.
- What was the largest recent ENGN insider trade?
- Grossman William (Interim Chief Medical Officer · Director) bought $10.1K of ENGN stock on Sep 22, 2026 at about $1.97 a share.
- When did an insider last buy ENGN shares?
- The most recent open-market purchase on file is Grossman William (Interim Chief Medical Officer · Director) buying $10.1K on Sep 22, 2026.
- Where does ENGN insider trading data come from?
- From the Form 4 filings enGene Therapeutics Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.